<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-09-23T17:08:59Z</responseDate><request verb="GetRecord" identifier="oai:www.repository.cam.ac.uk:1810/384272" metadataPrefix="uketd_dc">https://api.repository.cam.ac.uk/server/oai/request</request><GetRecord><record><header><identifier>oai:www.repository.cam.ac.uk:1810/384272</identifier><datestamp>2025-05-20T00:42:10Z</datestamp><setSpec>com_1810_221925</setSpec><setSpec>com_1810_34581</setSpec><setSpec>col_1810_224160</setSpec></header><metadata><uketd_dc:uketddc xmlns:uketd_dc="http://naca.central.cranfield.ac.uk/ethos-oai/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:uketdterms="http://naca.central.cranfield.ac.uk/ethos-oai/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://naca.central.cranfield.ac.uk/ethos-oai/2.0/ http://naca.central.cranfield.ac.uk/ethos-oai/2.0/uketd_dc.xsd">
   <dc:title>Modelling neuronal mitochondrial aminoacyl-tRNA synthetase defects</dc:title>
   <dc:identifier xsi:type="dcterms:DOI">https://doi.org/10.17863/CAM.118324</dc:identifier>
   <dc:creator>Podmanicky, Oliver</dc:creator>
   <uketdterms:advisor>Horvath, Rita</uketdterms:advisor>
   <dcterms:abstract>Mitochondrial diseases cover a broad group of disorders caused by mitochondrial dysfunction,
often affecting organs with high metabolic demand, such as the brain and skeletal muscle.
Mutations in mitochondrial aminoacyl-tRNA synthetase (MT-ARS) genes, which are crucial
for mitochondrial protein synthesis and energy production via oxidative phosphorylation, are
implicated in a variety of severe neurological and multisystemic diseases. Among these,
mutations in mitochondrial alanyl-tRNA synthetase (AARS2), mitochondrial glutamyl-tRNA
synthetase (EARS2), and mitochondrial arginyl-tRNA synthetase (RARS2) cause distinct
clinical manifestations including combined oxidative phosphorylation deficiency type 8
(COXPD8), characterised by leukoencephalopathy with ovarian failure, or cardiomyopathy,
leukoencephalopathy with thalamus and brainstem involvement and high lactate (LTBL), and
pontocerebellar hypoplasia type 6 (PCH6). Despite their significance, the underlying
pathological mechanisms remain poorly understood due to the lack of physiologically relevant
human models, as current research relies primarily on non-human models or patient-derived
fibroblasts that do not recapitulate the tissue-specific complexities of the nervous system. Here,
I address this unmet need by applying tissue-specific human models of the nervous system to
investigate the cellular impact of AARS2, EARS2 and RARS2 defects.
First, patient fibroblasts were reprogrammed into neuronal cells, which allows for a direct
comparison of different MT-ARS mutations. These in vitro models exhibit the tissue-specificity
of MT-ARS mutations by showing selective loss of mitochondrial respiratory chain complexes
in differentiated neurons but not in proliferating neural progenitor cells. RNA sequencing,
immunoblotting and mitochondrial respiratory analysis of these models demonstrate varying
degrees of mitochondrial dysfunction along with the activation of distinct compensatory
mechanisms and cellular stress responses, including the integrated stress response, and
impairment in neuronal development. Furthermore, I investigate how AARS2 mutations
associated with two distinct phenotypes impact mitochondrial protein synthesis in neurons in
vitro using a non-radioactive technique involving click chemistry.
In addition to developing neuronal models of MT-ARS defects, I sought to complement the
in vitro findings with a viable in vivo model of EARS2 deficiency. Given the housekeeping
role of MT-ARS, homozygous mutations in these genes are often embryonically lethal and in vivo models are rarely viable. Zebrafish offer a unique advantage in this regard, enabling viable
MT-ARS whole-body knockouts to investigate developmental and systemic consequences of
these mutations. I present new findings on the pathogenicity of EARS2 mutations in early
development and test potential therapeutic strategies for MT-ARS-related disorders in vivo
using a transgenic zebrafish model. Ears2 knockout zebrafish presented with abnormal
development, early lethality, reduced locomotor activity, and activation of cellular stress, which
was partially rescued by amino acid supplementation.</dcterms:abstract>
   <uketdterms:institution>University of Cambridge</uketdterms:institution>
   <dcterms:issued>2024-09-29</dcterms:issued>
   <dc:type>Thesis</dc:type>
   <uketdterms:qualificationlevel>Doctoral</uketdterms:qualificationlevel>
   <dc:language>eng</dc:language>
   <dcterms:isReferencedBy xsi:type="dcterms:URI">https://www.repository.cam.ac.uk/handle/1810/384272</dcterms:isReferencedBy>
   <dc:identifier xsi:type="dcterms:URI">https://apollo8-f-pro.lib.cam.ac.uk/bitstreams/a31af9a8-6cb0-4d16-8f91-f73a796c7b15/download</dc:identifier>
   <uketdterms:checksum xsi:type="uketdterms:MD5">b6d236bf6ee8892018bdc13753ee624a</uketdterms:checksum>
   <dcterms:license>https://apollo8-f-pro.lib.cam.ac.uk/bitstreams/920d6fef-7fd5-4e21-95a8-49d6ca4f4759/download</dcterms:license>
   <uketdterms:checksum xsi:type="uketdterms:MD5">87eda9de84448d1f82354d60eee3eb5f</uketdterms:checksum>
   <dc:rights>http://purl.org/NET/rdflicense/allrightsreserved</dc:rights>
   <dc:subject>aminoacyl-trna synthetase</dc:subject>
   <dc:subject>mitochondria</dc:subject>
   <dc:subject>translation</dc:subject>
   <dc:subject>AARS2</dc:subject>
   <dc:subject>EARS2</dc:subject>
   <dc:subject>RARS2</dc:subject>
</uketd_dc:uketddc>
</metadata></record></GetRecord></OAI-PMH>